Related Experiment Videos

Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor

P G Stalboerger1, C J Panetta, R D Simari

  • 1Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.

Insights

Plasmin degrades tissue factor pathway inhibitor (TFPI) in vascular cells and the vessel wall. This proteolysis reduces TFPI

Area of Science:

  • Biochemistry
  • Vascular Biology
  • Hemostasis and Thrombosis

Background:

  • Plasmin is a key protease in fibrinolysis and extracellular matrix remodeling.
  • In vitro studies suggest plasmin inactivates tissue factor pathway inhibitor (TFPI).
  • The in vivo relevance of plasmin's effect on TFPI in vascular cells and the vessel wall is unclear.

Purpose of the Study:

  • To investigate the effect of plasmin on cell surface and extracellular matrix (ECM)-associated TFPI.
  • To examine plasmin's impact on TFPI in cultured endothelial cells (EC) and in the vessel wall.
  • To assess the implications of plasmin-mediated TFPI degradation for coagulation and thrombolysis.

Main Methods:

  • Experiments using cultured EC and smooth muscle cells (SMC).
  • Treatment with plasmin and plasminogen.
  • Assays included amidolytic activity, fluorescence-activated cell sorting (FACS), Western blotting, and analysis of vessel wall and atherosclerotic plaque sections.

Main Results:

  • Plasmin significantly reduced TFPI activity and antigen on EC surfaces and in ECM.
  • Plasmin proteolyzed TFPI in cultured cells, vessel wall homogenates, and atherosclerotic plaques.
  • TFPI degradation by plasmin was associated with reduced anticoagulant activity.

Conclusions:

  • Plasmin proteolyses TFPI in vascular cells and the vessel wall.
  • This degradation removes TFPI from EC surfaces and the vessel intima.
  • Plasmin-mediated TFPI degradation may impact re-thrombosis risk after thrombolysis.

Related Concept Videos